The role of the endothelium in regulating coronary acadrenergic tone was evaluated in isolated coronary arterial rings from dogs with and without pacing-induced congestive heart failure (CHF). The maximal contractile response to methoxamine was attenuated approximately 43% (p<O.05) in both intact and denuded CHF rings compared with control. Conversely, norepinephrine-induced contractions were diminished 58% in intact CHF vessels and 39%o in denuded CHF vessels (p<0.05). Denudation did not alter responses to methoxamine but significantly (p<0.05) augmented the tension generated by norepinephrine in both control (1.7-fold) and CHF (2.4-fold) arteries. In both intact control and CHF coronary arteries, norepinephrine elicited rapid, transient relaxations that preceded slow, sustained contractions; the initial relaxation phase was endothelium dependent, because denudation eliminated the response. Relaxations to the selective ca2-adrenoceptor agonist BHT 920 were also dependent on the presence of an endothelium. At peak CHF, endothelium-dependent relaxations to norepinephrine and BHT 920 were enhanced, whereas relaxations to nitroglycerin and acetylcholine were unaltered. The data suggest that a-adrenergic tone in canine coronary arteries is diminished by pacing-induced CHF because of a decrease in rl-adrenoceptor-mediated constriction and an enhanced capacity of the endothelium to antagonize the direct vascular smooth muscle response of norepinephrine through endothelium-dependent, av2-adrenoceptor-mediated relaxations. (Circulation Research 1991;68:940-946) Adrenergic responses within the coronary vasculature are complex because of the existence of a mixed population of a-and /-adrenoceptors.,2 Also, coronary a-adrenergic receptors mediate vasoconstriction.3 However, both circulating and neurally released catecholamines exert a tonic vasodilatory effect on epicardial vessels via both f1-and 8,2-adrenoceptor activation.4 Furthermore, a2-adrenoceptors, located on the endothelium, may mediate the release of endothelium-derived relaxing factor (EDRF),5 resulting in direct relaxation or inhibition of contraction.6 Thus, a-adrenergic responses in large canine coronary arteries are a combination of both vasoconstrictor (a,-adrenoceptor) and vasodilator (a2-adrenoceptor) mechanisms.7
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The effect of congestive heart failure (CHF) on the adrenergic control of coronary arterial tone remains unknown. CHF is associated with an array of peripheral neurohumoral adjustments, including activation of the sympathetic nervous system.8 Rapid ventricular pacing in the dog produces hemodynamic and neurohumoral perturbations similar to those found in patients with CHF, including a rise in plasma norepinephrine.910 Indeed, tachycardia-induced heart failure has been described as a specific clinical syndrome in humans.'1 Preliminary in vitro studies indicate a diminished contractile responsiveness to a-adrenergic stimulation in endothelium-intact coronary arteries from dogs with pacing-induced heart failure.'2 Activation of the sympathetic nervous system may modify the integrated response within coronary vessels between al-adrenoceptor-mediated vascular smooth muscle constriction and a2-adrenoceptor-mediated, endothelium-dependent vasodilation. The physiological or pathophysiological role of EDRF within the coronary vasculature in CHF, however, has not been addressed. Consequently, the objective of the present study was to assess the influence of the endothelium on a-adrenoceptormediated contractions in epicardial coronary arteries from dogs with pacing-induced heart failure. The length-active tension relation in the left anterior descending and circumflex coronary arteries from both control and CHF dogs was examined in preliminary experiments, and the optimal resting tension was determined as 4 and 6 g, respectively. No difference was observed between vessels from the control and CHF groups.
Agonist Concentration-Effect Studies
Cumulative concentration-effect curves were constructed in intact and denuded rings after a 60-90-minute equilibration period. A minimum of five different agonists was administered to each individual preparation. The sequence of drug exposure was randomized, and consecutive curves were separated by a 60-minute wash period.
Adrenergic contractile activity was assessed using the selective a-agonist methoxamine (0.01-100 ,uM) and the mixed a-agonist norepinephrine (0.01-100 ,uM).
To determine the role of endothelial adrenoceptor function in CHF, the selective a2-agonist BHT 920 (0.1-100 ,uM) was administered to rings precontracted with 10 mM KCl, an approximate EC30 dose derived from preliminary experiments. General vessel responsiveness was assessed with KCl (20-80 mM), whereas relaxations elicited by acetylcholine (0.1-10 ,M) (in preparations precontracted with either 20 mM KCl or 2.0 ,uM prostaglandin [PG] F2a) were used to ascertain the integrity of the endothelium. The capacity of the arterial segments to relax to an endothelium-independent agent, nitroglycerin (1.0 nM-10 ,uM), was also evaluated (all rings precontracted with 2 ,uM PGF2a).
Drugs and Solutions
The following drugs were used: acetylcholine iodide (Sigma Chemical Co., St. Louis), BHT Contractile responses to norepinephrine were significantly enhanced, in both control and CHF rings, by the mechanical disruption of the endothelium ( Figure iB) ; the maximal tension generated in control vessels was increased 1.7-fold (1.49±0.17 g/mm2 versus 2.47±0.25 g/mm2; p<0.05, intact versus denuded) and in CHF vessels was increased 2.4-fold (0.62±0.09 g/mm2 versus 1.51±0.14 g/mm2; p<0.05, intact versus denuded).
Independent of the endothelium, CHF arteries pulled significantly less tension to norepinephrine as compared with control arteries ( Figure 1B) . The maximal response to norepinephrine in denuded CHF segments was 61% of the denuded control response, whereas intact CHF vessels produced only 42% of the intact control response to norepinephrine. The maximal contractile force developed in denuded CHF rings (1.51±0.14 g/mm2) was similar to that evoked by the agonist in intact control rings epinephrine response (see below) precluded EC50
determination.
In individual rings with an intact endothelium, norepinephrine evoked a dose-related biphasic response that was characterized by an initial rapid decrease in tension, with a peak response occurring in less than 30 seconds, followed by a slow, sustained contraction, with a peak response occurring over minutes (Figures 2A and 2B ). Low concentrations of norepinephrine (<0.1 ,uM) generally produced contractions only. Differences were noted in the proportion of control and CHF preparations that responded biphasically to norepinephrine; endothelium-dependent relaxations occurred in only 17 of 37 control arteries examined compared with 36 of 39 CHF arteries studied (p<0.05; x2). In coronary arteries that displayed biphasic responses, the concentration of norepinephrine at which endothelium-dependent relaxations first appeared was 10-fold lower in CHF arteries compared with control ( Figure 3) . The magnitude of the relaxation for any given dose of norepi- Vessels with a functional intimal layer never evoked biphasic relaxations and contractions to the al-agonist methoxamine. Similarly, biphasic norepinephrine responses (to individual dosage increments) were never observed in control or CHF rings whose intimal surface had been removed intentionally ( Figure 2C ). Concentrations of norepinephrine up to 10 ,uM invariably produced contractions in denuded preparations. Doses of more than 10 ,M elicited relaxations that were slow to develop and were sustained over time in both intact and denuded rings. Figure 4 shows that intact control segments responded to BHT 920 with small dose-dependent relaxations. Conversely, denuded control rings contracted to the a2-agonist over the entire range of concentrations examined. The effects of BHT 920 in intact and denuded CHF preparations were similar but more profound. Relative to control, maximal contractions to BHT 920 were depressed in denuded CHF arteries, whereas BHT 920-induced relaxations were enhanced in intact CHF vessels.
The maximal force generated in response to In coronary arteries with an intact endothelium, acetylcholine produced dose-dependent relaxations in vessels precontracted with both KCl (20 mM) and PGF2a (2 ,uM) ( Figure 5 ). The magnitude of relaxation was independent of the contractile agent used, and no significant difference was observed between CHF and control segments. Acetylcholine relaxations were maximal at a concentration of 10 ,uM; further increments in dose either had no effect or caused contractions. Relaxations were never detected in denuded coronary vessels.
The capacity of the coronary vessels to relax to an endothelium-independent agent, as assessed by nitroglycerin responses, was comparable in control and CHF segments. Relaxation of 100% was achieved in all rings studied. Removal of the endothelium enhanced the potency of nitroglycerin to a similar extent in control and CHF rings, as reflected by a significant decrease in EC50 values: control, 7.3 (5.5-9.7) 
Discussion
The present findings demonstrate that pacinginduced heart failure augments a-adrenergicinduced, endothelium-dependent relaxations in canine coronary arteries. The integrated response between a1-adrenoceptor-mediated contractions and a2-adrenoceptor-mediated relaxations is modified at peak heart failure, such that the constrictor signal is attenuated, whereas the dilator signal is potentiated.
This conclusion is based on the following observations: 1) denudation augmented norepinephrineevoked contractions to a greater extent in CHF vessels relative to control vessels; 2) intact but not denuded coronary arteries responded to norepinephrine with slow, sustained contractions preceded by FIGURE 5 . Cumulative concentration-effect curves constructed for acetylcholine in intact coronary arteries from control and heart failure dogs. Tone was induced with either 20 mMKCl or 2x 1o6 Mprostaglandin (PG) F2a; 100% represents relaxation to baseline. o, Control/KCl; *, heart failure/ KCl; A, control/PGF2a; A, heart failure/PGF2,. rapid, reversible relaxations; 3) the relaxation component of the biphasic response occurred more frequently, required a lower threshold concentration of norepinephrine, and was of a greater magnitude in CHF arteries compared with control; 4) the maximal tension elicited by norepinephrine in coronary arteries was significantly reduced at peak CHF, but more so in intact as compared with denuded vessels; 5) contractions in response to the selective a,-adrenoceptor agonist methoxamine were diminished to a similar extent in both intact and denuded CHF preparations relative to control preparations; and 6) relaxations induced by BHT 920 in intact vessels were enhanced at peak CHF, whereas contractions generated in denuded preparations to the selective a2-agonist were depressed.
Previous investigators have demonstrated a loss of endothelium-dependent relaxations in hypertension16 and atherosclerosis.17 A decrease in the capacity of aortic and pulmonic vessels to relax in response to acetylcholine also has been noted in a rat model of CHF.18 Our investigation is unique in that it is the first report of an enhanced endothelial modulatory effect in a disease state.
Cocks and Angus6 found that in canine coronary arteries in vitro, norepinephrine-induced contractions were more powerful and sensitive in vessels whose endothelium had been mechanically removed. Although they concluded that norepinephrine could stimulate the release of EDRF, under normal resting tone, the contractile effect of norepinephrine consistently overrode the relaxation response to EDRF.6 In our study, the predominant response of intact coronary rings to a-adrenergic stimulation likewise was vascular smooth muscle constriction. The stimulus for relaxation, however, was enhanced at peak CHF, such that norepinephrine-mediated relaxations became unmasked, directly opposing the contractile effect of the mixed a-agonist. Biphasic norepinephrine responses were absent in denuded segments, suggesting that the initial relaxation component found in intact coronary arteries was mediated through an endothelium-dependent mechanism. The reversibility of the norepinephrine-induced relaxations is comparable to that observed for acetylcholine, further corroborating a role for EDRF. In addition to endothelium-dependent relaxations, slow sustained relaxations also were observed in both denuded as well as intact control and CHF rings at very high concentrations of norepinephrine (>10 ,uM). These relaxations, even in the presence of propranolol, were conceivably mediated by ,B-adrenoceptors because of the predominance of P-adrenoceptors in coronary arteries.4 '19 In the present study, the selective a2-adrenoceptor In summary, pacing-induced CHF in the dog is associated with a shift in coronary a-adrenergic constrictor/dilator balance, such that a1-adrenoceptormediated contractions are attenuated, and endothelium-dependent a2-adrenoceptor-mediated relaxations are enhanced. As coronary a-adrenergic-induced constriction is capable of competing with metabolically induced vasodilatation,3 such an alteration may be an important protective response of the coronary vasculature in the setting of CHF. It is prudent to emphasize that the data were derived from isolated coronary arteries from male mongrel dogs with pacing-induced CHF; the implications for the intact human coronary circulation are unknown. Although the ultimate significance of these findings remains to be determined, it is clear that pathophysiological conditions, such as pacing-induced CHF, can lead to an increase in endothelial modulatory function.
